Lynda Charters

Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.

Articles

FDA approves Dextenza for third indication: Ocular itching from allergic conjunctivitis

October 12, 2021

Article

The FDA approved Ocular Therapeutix Inc.’s Supplemental New Drug Application (sNDA) that further extends Dextenza’s (dexamethasone ophthalmic insert) 0.4 mg indications, the company announced Monday.

OAKS and DERBY studies demonstrate efficacy of pegcetacoplan for Geographic Atrophy

October 11, 2021

Article

During the American Society of Retina Specialists 2021 annual meeting, David Boyer, MD, told attendees that pegcetacoplan used to treat geographic atrophy proved to be well tolerated by patients in the phase 3 DERBY and OAKS studies.

Study details Port Delivery System with ranibizumab in nAMD

October 11, 2021

Article

In a presentation at the American Society of Retina Specialists 2021 annual meeting, Arshad Khanani, MD, MA, noted that investigators achieved results similar to those in patients treated with monthly ranibizumab injections for neovascular age-related macular degeneration.

Commercial OCT: Tracking macrophages in the macular circulation

October 10, 2021

Article

Speaking at the American Society of Retina Specialists 2021 annual meeting, Richard B. Rosen, MD, DSc (Hon) noted that clinical OCT and offers a new clinical biomarker for tracking the onset and progression of retinal vascular disease and the response to therapy.